ARCHIVES

Rituximab Maintenance Improves Survival In Relapse

This article is from The Cancer Letter archive.

Vol. 32 No. 2 | February 27, 2009

Download PDF Visit The Full Archive

Related Articles

Group Chairmen Accept Most Changes In Terms Of Award, Object To CTEP Adjustments

December 2, 1988

It is The First FDA Withdrawl Of An Accelerated Approval

November 18, 2011

FDA Approves Evista for Breast Cancer Risk Reduction.

September 14, 2007

Roswell Park, Karmanos Read The Cancer Letter Interactive.

December 1, 2000

In Brief: FDA Advisors Ask Cetus To Refine IL-2 Application; NIH Reauthorization Introduced

August 3, 1990

Harold Varmus Addresses the NCI Board of Scientific Advisors

March 8, 2013